Found 1 results
Filters: Author is B. Vural  [Clear All Filters]
F. Atalar, Vural, B., Ciftci, C., Demirkan, A., Akan, G., Susleyici-Duman, B., Gunay, D., Akpinar, B., Sagbas, E., Ozbek, U., and Buyukdevrim, A. S., 11β-hydroxysteroid dehydrogenase type 1 gene expression is increased in ascending aorta tissue of metabolic syndrome patients with coronary artery disease, vol. 11, pp. 3122-3132, 2012.
Alberti L, Girola A, Gilardini L, Conti A, et al. (2007). Type 2 diabetes and metabolic syndrome are associated with increased expression of 11β-hydroxysteroid dehydrogenase 1 in obese subjects. Int. J. Obes. 31: 1826-1831. PMid:17593901   Baker AR, Silva NF, Quinn DW, Harte AL, et al. (2006). Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc. Diabetol. 5: 1. PMid:16412224 PMCid:1352345   Balkau B, Vernay M, Mhamdi L, Novak M, et al. (2003). The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab. 29: 526-532.   Boullu-Ciocca S, Dutour A, Guillaume V, Achard V, et al. (2005). Postnatal diet-induced obesity in rats upregulates systemic and adipose tissue glucocorticoid metabolism during development and in adulthood: its relationship with the metabolic syndrome. Diabetes 54: 197-203. PMid:15616029   Bujalska IJ, Kumar S and Stewart PM (1997). Does central obesity reflect "Cushing's disease of the omentum?" Lancet 349: 1210-1213.   Bujalska IJ, Kumar S, Hewison M and Stewart PM (1999). Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology 140: 3188-3196. PMid:10385414   Bujalska IJ, Walker EA, Hewison M and Stewart PM (2002a). A switch in dehydrogenase to reductase activity of 11β-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J. Clin. Endocrinol. Metab. 87: 1205-1210. PMid:11889189   Bujalska IJ, Walker EA, Tomlinson JW, Hewison M, et al. (2002b). 11β-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. Endocr. Res. 28: 449-461. PMid:12530648   Bujalska IJ, Durrani OM, Abbott J, Onyimba CU, et al. (2007). Characterisation of 11β-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat. J. Endocrinol. 192: 279-288. PMid:17283228 PMCid:1994563   Dallman MF, Pecoraro N, Akana SF, La Fleur SE, et al. (2003). Chronic stress and obesity: a new view of "comfort food". Proc. Natl. Acad. Sci. U. S. A. 100: 11696-11701. PMid:12975524 PMCid:208820   Desbriere R, Vuaroqueaux V, Achard V, Boullu-Ciocca S, et al. (2006). 11β-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 14: 794-798. PMid:16855188   Hermanowski-Vosatka A, Gerhold D, Mundt SS, Loving VA, et al. (2000). PPARα agonists reduce 11β-hydroxysteroid dehydrogenase type 1 in the liver. Biochem. Biophys. Res. Commun. 279: 330-336. PMid:11118287   Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, et al. (2005). 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 202: 517-527. PMid:16103409 PMCid:2212859   Hotamisligil GS and Spiegelman BM (1994). Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 43: 1271-1278. PMid:7926300   Iacobellis G, Ribaudo MC, Assael F, Vecci E, et al. (2003). Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J. Clin. Endocrinol. Metab. 88: 5163-5168. PMid:14602744   Iacobellis G, Corradi D and Sharma AM (2005a). Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat. Clin. Pract. Cardiovasc. Med. 2: 536-543. PMid:16186852   Iacobellis G, Pistilli D, Gucciardo M, Leonetti F, et al. (2005b). Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine 29: 251-255. PMid:15749025   IDF (International Diabetes Federation) (2005). The IDF Concensus Worldwide Definition of the Metabolic Syndrome. Available at []. Accessed October 19, 2005.   Kolak M, Yki-Jarvinen H, Kannisto K, Tiikkainen M, et al. (2007). Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 92: 720-724. PMid:17148569   Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, et al. (1997). 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U. S. A. 94: 14924-14929. PMid:9405715 PMCid:25139   Lindsay RS, Wake DJ, Nair S, Bunt J, et al. (2003). Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 88: 2738-2744. PMid:12788882   Liu J, Wang L, Zhang A, Di W, et al. (2011). Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity. Endocr. J. 58: 199-209. PMid:21325744   Liu Y, Sun WL, Sun Y, Hu G, et al. (2006). Role of 11-β-hydroxysteroid dehydrogenase type 1 in differentiation of 3T3- L1 cells and in rats with diet-induced obesity. Acta Pharmacol. Sin. 27: 588-596. PMid:16626514   Masuzaki H and Flier JS (2003). Tissue-specific glucocorticoid reactivating enzyme, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) - a promising drug target for the treatment of metabolic syndrome. Curr. Drug Targets Immune. Endocr. Metabol. Disord. 3: 255-262. PMid:14683456   Masuzaki H, Paterson J, Shinyama H, Morton NM, et al. (2001). A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170. PMid:11739957   Morton NM, Ramage L and Seckl JR (2004). Down-regulation of adipose 11β-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease. Endocrinology 145: 2707-2712. PMid:15044372   Nakano S, Inada Y, Masuzaki H, Tanaka T, et al. (2007). Bezafibrate regulates the expression and enzyme activity of 11β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 292: E1213-E1222. PMid:17190905   Onat A (2004). Lipids, lipoproteins and apolipoproteins among turks, and impact on coronary heart disease. Anadolu Kardiyol. Derg. 4: 236-245. PMid:15355827   Paulsen SK, Pedersen SB, Fisker S and Richelsen B (2007). 11β-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring) 15: 1954-1960. PMid:17712112   Reape TJ and Groot PH (1999). Chemokines and atherosclerosis. Atherosclerosis 147: 213-225.   Rebuffe-Scrive M, Bronnegard M, Nilsson A, Eldh J, et al. (1990). Steroid hormone receptors in human adipose tissues. J. Clin. Endocrinol. Metab. 71: 1215-1219. PMid:2229280   Sheppard KE and Autelitano DJ (2002). 11β-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology 143: 198-204. PMid:11751610   Silaghi A, Achard V, Paulmyer-Lacroix O, Scridon T, et al. (2007). Expression of adrenomedullin in human epicardial adipose tissue: role of coronary status. Am. J. Physiol. Endocrinol. Metab. 293: E1443-E1450. PMid:17878224   Staab CA and Maser E (2010). 11β-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. J. Steroid Biochem. Mol. Biol. 119: 56-72. PMid:20045052   Stewart PM (2003). Tissue-specific Cushing's syndrome, 11β-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur. J. Endocrinol. 149: 163-168. PMid:12943516   Tomlinson JW, Walker EA, Bujalska IJ, Draper N, et al. (2004). 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 25: 831-866. PMid:15466942   Trevisan M, Liu J, Bahsas FB and Menotti A (1998). Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am. J. Epidemiol. 148: 958-966. PMid:9829867   Weber C, Schober A and Zernecke A (2004). Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler. Thromb. Vasc. Biol. 24: 1997-2008. PMid:15319268   Wilson PW, Kannel WB, Silbershatz H and D'Agostino RB (1999). Clustering of metabolic factors and coronary heart disease. Arch. Intern. Med. 159: 1104-1109. PMid:10335688   Xu H, Barnes GT, Yang Q, Tan G, et al. (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112: 1821-1830. PMid:14679177 PMCid:296998